Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn...
https://pubmed.ncbi.nlm.nih.gov/26412456/Actively Recruiting
Led by Elsan · Updated on 2026-04-23
35
Participants Needed
1
Research Sites
39 weeks
Total Duration
Researchers are evaluating stereotactic radiotherapy to restore the effectiveness of anti-PD1 immunotherapy in patients with metastatic solid tumors who initially responded well to immunotherapy for more than six months but later experienced disease progression. The study focuses on the abscopal effect, where radiation to one tumor site may impact other untreated metastases. Participants will receive stereotactic radiotherapy in three sessions, each delivering 8 Gy of radiation lasting about 20 minutes, spaced 72 hours apart on Day 1, Day 4, and Day 7. This treatment is given alongside ongoing anti-PD1 immunotherapy. Prior to radiotherapy, a CT scan without contrast is performed to plan precise treatment. The radiotherapy device is used according to its approved medical indications. During the study, participants will be closely monitored with assessments up to 12 months after radiotherapy. Researchers will measure tumor response using iRECIST and RECIST 1.1 criteria on both irradiated and untreated lesions to evaluate the abscopal effect. They will also track progression-free survival, overall survival, adverse events, and timing of any new systemic treatments. The primary outcome is the objective response rate at 3 months post-radiotherapy in patients with confirmed progression after initial immunotherapy response.
CONDITIONS
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
V
Vincent ATALLAH, Dr
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Elsan
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 1 to 2 weeks
Participants receive stereotactic radiotherapy consisting of 3 sessions of 8 Gy each, lasting about 20 minutes per session with 72 hours between sessions, alongside ongoing anti-PD1 immunotherapy. A radiotherapy CT scan is performed before radiotherapy to prepare the treatment plan.
3 radiotherapy sessions and 1 CT scan visit
Duration - Up to 12 months
Participants are monitored for safety and treatment efficacy for up to 12 months after stereotactic radiotherapy.
Regular visits during the 12-month follow-up period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Hossein Borghaei, Luis Paz-Ares, Leora Horn...
https://pubmed.ncbi.nlm.nih.gov/26412456/M Zahidunnabi Dewan, Ashley E Galloway, Noriko Kawashima...
https://pubmed.ncbi.nlm.nih.gov/19706802/Claire Vanpouille-Box, Amandine Alard, Molykutty J Aryankalayil...
https://pubmed.ncbi.nlm.nih.gov/28598415/Julie Brahmer, Karen L Reckamp, Paul Baas...
https://pubmed.ncbi.nlm.nih.gov/26028407/Steven J Hatten, Eric J Lehrer, Jenn Liao...
https://pubmed.ncbi.nlm.nih.gov/35372719/Jérôme Doyen, Benjamin Besse, Matthieu Texier...
https://pubmed.ncbi.nlm.nih.gov/34810130/Michael A Postow, Margaret K Callahan, Christopher A Barker...
https://pubmed.ncbi.nlm.nih.gov/22397654/Lesley Seymour, Jan Bogaerts, Andrea Perrone...
https://pubmed.ncbi.nlm.nih.gov/28271869/Sayeda Yasmin-Karim, Bashkim Ziberi, Johanna Wirtz...
https://pubmed.ncbi.nlm.nih.gov/34530092/Wilfred Ngwa, Omoruyi Credit Irabor, Jonathan D Schoenfeld...
https://pubmed.ncbi.nlm.nih.gov/29449659/Elsan
Lead Sponsor